CD4+ T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea.
In order to determine the role of CD4+ and CD8+ T-cells and of interleukin-5 (IL-5) in causing antigen-induced eosinophil infiltration into the site of airway late-phase reaction, we examined the effect of the in vivo depletion of CD4+ and CD8+ T-cells on the eosinophil infiltration of the trachea induced by antigen inhalation in mice. We also studied the effect of anti-murine IL-5 monoclonal antibody (mAb) on the antigen-induced eosinophil infiltration in the trachea. The eosinophil infiltration into the trachea of ovalbumin (OVA)-sensitized BALB/c mice began to increase 9 h after OVA inhalation and persisted for more than 48 h. The in vivo depletion of CD4+ T-cells by pretreatment with anti-L3T4 mAb significantly decreased the eosinophil infiltration induced by OVA inhalation in the trachea of sensitized mice. However, the in vivo depletion of CD8+ T-cells by pretreatment with anti-Lyt-2 mAb had no significant effect on OVA-induced eosinophil infiltration in the trachea. Pretreatment with anti-murine IL-5 mAb also decreased OVA-induced eosinophil infiltration in the trachea. In contrast, neither disodium cromoglycate nor a selective antagonist for platelet-activating factor CV-6209 decreased OVA-induced airway eosinophilia in the mouse. Our results provide direct evidence that CD4+ but not CD8+ T-cells mediate antigen-induced eosinophil recruitment in the airways and that IL-5 mediates this eosinophil recruitment.
Second Department of Internal Medicine, Chiba University School of Medicine, Japan.
H
H
Nakajima
I
I
Iwamoto
S
S
Tomoe
R
R
Matsumura
H
H
Tomioka
K
K
Takatsu
S
S
Yoshida
D000280:Administration, Inhalation; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D004205:Cromolyn Sodium / Q000494:pharmacology / Q000627:therapeutic use; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D005069:Evaluation Studies as Topic; D006968:Hypersensitivity, Delayed / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D007274:Injections, Intraperitoneal; D015848:Interleukin-5 / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000009:adverse effects*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011726:Pyridinium Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014132:Trachea / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015848:Interleukin-5; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; C053321:CV 6209; D010047:Ovalbumin; D004205:Cromolyn Sodium